Clindamycin
Clindamycin
300 and 600 mg ampoule
Bone and joint infections: Treatment of bone and joint infections, including acute hematogenous
osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of
chronic bone and joint infections caused by susceptible organisms.
Gynecological infections: Treatment of gynecologic infections, including endometritis, nongonococcal
tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible
anaerobes.
Intraabdominal infections: Treatment of intraabdominal infections, including peritonitis and
intraabdominal abscess caused by susceptible anaerobic organisms.
Lower respiratory tract infections: Treatment of lower respiratory tract infections, including pneumonia,
empyema, and lung abscess caused by susceptible anaerobes, Streptococcus pneumoniae, other
streptococci (except Enterococcus faecalis), and S. aureus.
Septicemia: Treatment of septicemia caused by S. aureus, streptococci (except E. faecalis), and
susceptible anaerobes.
Skin and soft tissue infection: Treatment of skin and soft tissue infection caused by Streptococcus
pyogenes, S. aureus, and susceptible anaerobes.
Mechanism of Action:
Reversibly binds to 50S ribosomal subunits preventing peptide bond formation thus inhibiting bacterial protein synthesis; bacteriostatic or bactericidal depending on drug concentration, infection site, and organism.
Method of Administration:
IM, IV: 600 to 2,700 mg/day in 2 to 4 divided doses, up to 4,800 mg/day IV (in divided doses) has been used in life-threatening infections.
Notes
Contraindications:
Hypersensitivity to clindamycin, lincomycin, or any component of the formulation.
Interactions:
CYP3A4 Inducers: May decrease the serum concentration of Clindamycin (Systemic). Risk C:
Monitor therapy
CYP3A4 Inhibitors: May increase the serum concentration of Clindamycin (Systemic). Risk C:
Monitor therapy
Pregnancy and Lactation:
Pregnancy category B, Use with caution in breast-feeding
Warning and Precaution:
- Renal toxicity: Acute kidney injury including acute renal failure has been reported.
- Superinfection: Use may result in overgrowth of nonsusceptible organisms, particularly yeast. Should
superinfection occur, appropriate measures should be taken as indicated by the clinical situation.
Adverse Reactions:
Dermatologic: Maculopapular rash, urticaria, vesiculobullous dermatitis
Gastrointestinal: Abdominal pain, Clostridioides difficile-associated diarrhea, Clostridioides difficile colitis, diarrhea, esophagitis, nausea, vomiting
Genitourinary: Azotemia, oliguria, proteinuria
Hepatic: Abnormal hepatic function tests, jaundice
Storage:
Store below 30 and protect from light and moisture.